The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
Millions of stroke survivors across the world may soon have a new defense
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
Subscribe To Our Newsletter & Stay Updated
